Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

181. [Efficacy and safety of the immunoregulatory drugs interferon beta and glatiramer in the treatment of relapsing remitting multiple sclerosis]

[Efficacy and safety of the immunoregulatory drugs interferon beta and glatiramer in the treatment of relapsing remitting multiple sclerosis] Eficacia y seguridad de los fármacos inmunoreguladores, interferón beta y glatiramero, en la esclerosis múltiple remitente recidivante [Efficacy and safety of the immunoregulatory drugs interferon beta and glatiramer in the treatment of relapsing remitting multiple sclerosis] Eficacia y seguridad de los fármacos inmunoreguladores, interferón beta y (...) glatiramero, en la esclerosis múltiple remitente recidivante [Efficacy and safety of the immunoregulatory drugs interferon beta and glatiramer in the treatment of relapsing remitting multiple sclerosis] Martínez Férez IM, Flores Moreno S, Rodríguez López R Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Martínez Férez IM, Flores Moreno S, Rodríguez

Health Technology Assessment (HTA) Database.2013

182. Botulinum toxin type a (Botox) - Management of urinary incontinence in adult patients with neurogenic detrusor overactivity due to subcervical spinal cord injury (traumatic or non-traumatic) or multiple sclerosis

Botulinum toxin type a (Botox) - Management of urinary incontinence in adult patients with neurogenic detrusor overactivity due to subcervical spinal cord injury (traumatic or non-traumatic) or multiple sclerosis

Scottish Medicines Consortium2013

183. A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis

A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis 23695501 2013 09 04 2013 11 08 2017 02 20 1468-330X 84 10 2013 Oct Journal of neurology, neurosurgery, and psychiatry J. Neurol. Neurosurg. Psychiatr. A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue (...) management programme (FACETS) for people with multiple sclerosis. 1092-9 10.1136/jnnp-2012-303816 Fatigue is a common and troubling symptom for people with multiple sclerosis (MS). To evaluate the effectiveness and cost-effectiveness of a six-session group-based programme for managing MS-fatigue (Fatigue: Applying Cognitive behavioural and Energy effectiveness Techniques to lifeStyle (FACETS)). Three-centre parallel arm randomised controlled trial with economic evaluation. Patients with MS and

EvidenceUpdates2013 Full Text: Link to full Text with Trip Pro

184. Laquinimod for multiple sclerosis.

Laquinimod for multiple sclerosis. BACKGROUND: Multiple sclerosis (MS) is a chronic immune-mediated, inflammatory, demyelinating, neurodegenerative disorder of the central nervous system, and it causes major socioeconomic burden for the individual patient and for society. An inflammatory pathology occurs during the early relapsing stage of MS and a neurodegenerative pathology dominates the later progressive stage of the disease. Not all MS patients respond adequately to currently available (...) disease-modifying drugs (DMDs). Alternative MS treatments with new modes of action are required to expand the current options for disease-modifying therapies (DMTs) and to aim for freedom from relapses, inflammatory lesions, disability progression and neurodegeneration. Laquinimod has dual properties of immunomodulation and neuroprotection and is a potentially promising new oral DMD in the treatment of relapsing MS. OBJECTIVES: To assess the effectiveness and safety profile of laquinimod

Cochrane2013

185. Group exercise training for balance, functional status, spasticity, fatigue and quality of life in multiple sclerosis: a randomized controlled trial

Group exercise training for balance, functional status, spasticity, fatigue and quality of life in multiple sclerosis: a randomized controlled trial 23543341 2013 08 06 2014 03 26 2014 07 31 1477-0873 27 9 2013 Sep Clinical rehabilitation Clin Rehabil Group exercise training for balance, functional status, spasticity, fatigue and quality of life in multiple sclerosis: a randomized controlled trial. 813-22 10.1177/0269215513481047 To determine the effectiveness of group exercise training (...) on balance, functional status, spasticity, fatigue and quality of life in patients with multiple sclerosis. A randomized single-blind controlled study. University hospital, outpatient physical therapy department. Ambulatory patients with multiple sclerosis. Exercise group completed a 12-week group exercise programme under the physical therapists' supervision. Control group was included in the waiting list. The primary outcome measures were the Berg Balance Scale, 10-metre walk test, 10-steps climbing

EvidenceUpdates2013

186. Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis

Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis 23223533 2013 01 15 2013 03 07 2013 01 15 1526-632X 80 3 2013 Jan 15 Neurology Neurology Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. 234-41 10.1212/WNL.0b013e31827debeb To assess in a large population of patients with clinically isolated syndrome (CIS) the relevance of brain lesion location and frequency in predicting 1-year conversion (...) to multiple sclerosis (MS). In this multicenter, retrospective study, clinical and MRI data at onset and clinical follow-up at 1 year were collected for 1,165 patients with CIS. On T2-weighted MRI, we generated lesion probability maps of white matter (WM) lesion location and frequency. Voxelwise analyses were performed with a nonparametric permutation-based approach (p < 0.05, cluster-corrected). In CIS patients with hemispheric, multifocal, and brainstem/cerebellar onset, lesion probability map clusters were seen

EvidenceUpdates2013

187. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. BACKGROUND: Daclizumab, a humanised monoclonal antibody, modulates interleukin-2 signalling by blocking the α subunit (CD25) of the interleukin-2 receptor. We assessed whether daclizumab high-yield process (HYP) would be effective when given as monotherapy for a 1 year treatment period in patients with relapsing-remitting multiple sclerosis. METHODS: We did (...) a randomised, double-blind, placebo-controlled trial at 76 centres in the Czech Republic, Germany, Hungary, India, Poland, Russia, Ukraine, Turkey, and the UK between Feb 15, 2008, and May 14, 2010. Patients aged 18-55 years with relapsing-remitting multiple sclerosis were randomly assigned (1:1:1), via a central interactive voice response system, to subcutaneous injections of daclizumab HYP 150 mg or 300 mg, or placebo, every 4 weeks for 52 weeks. Patients and study personnel were masked to treatment

Lancet2013

189. Randomized study combining interferon and glatiramer acetate in multiple sclerosis

Randomized study combining interferon and glatiramer acetate in multiple sclerosis 23424159 2013 04 18 2013 06 14 2017 02 20 1531-8249 73 3 2013 Mar Annals of neurology Ann. Neurol. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. 327-40 10.1002/ana.23863 A double-blind, randomized, controlled study was undertaken to determine whether combined use of interferon β-1a (IFN) 30 μg intramuscularly weekly and glatiramer acetate (GA) 20 mg daily is more efficacious (...) than either agent alone in relapsing-remitting multiple sclerosis. A total of 1,008 participants were randomized and followed until the last participant enrolled completed 3 years. The primary endpoint was reduction in annualized relapse rate utilizing a strict definition of relapse. Secondary outcomes included time to confirmed disability, Multiple Sclerosis Functional Composite (MSFC) score, and magnetic resonance imaging (MRI) metrics. Combination IFN+GA was not superior to the better

EvidenceUpdates2013 Full Text: Link to full Text with Trip Pro

190. [Clinical practice guideline of care for people with multiple sclerosis]

[Clinical practice guideline of care for people with multiple sclerosis] Guia de practica clinica sobre la atencion a las personas con esclerosis multiple [Clinical practice guideline of care for people with multiple sclerosis] Guia de practica clinica sobre la atencion a las personas con esclerosis multiple [Clinical practice guideline of care for people with multiple sclerosis] Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Guia de practica clinica sobre la atencion a las personas con esclerosis multiple. [Clinical practice guideline of care for people with multiple sclerosis] Barcelona: Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA). 2012 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Multiple Sclerosis; Practice Guideline Language Published Spanish Country

Health Technology Assessment (HTA) Database.2013

191. A pilot randomised controlled trial of an internet-based cognitive behavioural therapy self-management programme (MS Invigor8) for multiple sclerosis fatigue

A pilot randomised controlled trial of an internet-based cognitive behavioural therapy self-management programme (MS Invigor8) for multiple sclerosis fatigue A pilot randomised controlled trial of an internet-based cognitive behavioural therapy self-management programme (MS Invigor8) for multiple sclerosis fatigue A pilot randomised controlled trial of an internet-based cognitive behavioural therapy self-management programme (MS Invigor8) for multiple sclerosis fatigue Moss-Morris R, McCrone P (...) of multiple sclerosis (MS) fatigue. The authors concluded that the programme could be clinically effective and cost-effective, and more research was needed. The analysis was based on a pilot trial and provided preliminary information on the cost-effectiveness of the intervention. The authors’ conclusions appear to be valid for the analysis presented. Type of economic evaluation Cost-utility analysis Study objective This study examined the cost-effectiveness of internet-based cognitive

NHS Economic Evaluation Database.2013

200. Tecfidera (dimethyl fumarate) - To treat adults with relapsing forms of multiple sclerosis (MS).

Tecfidera (dimethyl fumarate) - To treat adults with relapsing forms of multiple sclerosis (MS). Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Tecfidera (dimethyl fumarate) Delayed-Release Capsules Company: Biogen Idec, Inc. Application No.: 204063 Approval Date: 3/27/2013 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF

FDA - Drug Approval Package2013